KKR proposes plan to buy Walgreens in $70B deal

Amy Baxter | | Health Exec | Policy & Regulations
Target health care costs.

Private equity group KKR has offered a $70 billion buyout proposal to Walgreens Boots Alliance, the Financial Times reported.

Rumors of the deal were first reported last week. It would bring Walgreens from a public company to private ownership, and KKR would need other big investors to complete the deal, according to the Financial Times. In addition, shareholders and senior management at Walgreens are in talks to contribute to taking the company private in some capacity. The company’s chairman, Stefano Pessina, owns 16% of the business.

Talks of a private equity deal come at a time when Walgreens has seen a major decline in its stock price, with a drop of nearly 20% from January through October this year. The deal would be one of the biggest private takeovers ever and could prove to be difficult, particularly as Walgreens has enacted cost-cutting measures by cutting stores and laying off employees to save a targeted $1.8 billion by 2022.

KKR has been a long-time investor with Walgreens and backed the company’s 2007 buyout of Boots Alliance.

See the full story below:

KKR outlines Walgreens Boots $70bn takeover plan

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Report: UnitedHealth under investigation by DOJ for Medicare Advantage upcoding
FDA approves first therapy for very rare lipid storage disorder
FDA announces Class I recall of Boston Scientific pacemakers—replacement may be necessary
FDA ends semaglutide shortage, closing the door on compounded Wegovy, Ozempic
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”